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Abstract 
The P2X7 purinergic receptor is an ATP-gated cation channel with an emerging role in neoplasia. In this 
study we demonstrate that the human KG-1 cell line, a model of acute myelogenous leukaemia, expresses 
functional P2X7. RT-PCR and immunochemical techniques demonstrated the presence of P2X7 mRNA 
and protein respectively in KG-l cells, as well as in positive control multiple myeloma RPMI 8226 cells. 
Flow cytometric measurements demonstrated that ATP induced ethidium(+) uptake into KG-l cells 
suspended in sucrose medium (EC(50) of ∼3 μM), but not into cells in NaCl medium. In contrast, ATP 
induced ethidium(+) uptake into RPMI 8226 cells suspended in either sucrose or NaCl medium (EC(50) of 
∼3 or ∼99 μM, respectively), as well as into RPMI 8226 cells in KCl medium (EC(50) of ∼18 μM). BzATP 
and to a lesser extent ATPγS and αβ-methylene ATP, but not ADP or UTP, also induced ethidium(+) uptake 
into KG-1 cells. ATP-induced ethidium(+) uptake was completely impaired by the P2X7 antagonists, 
AZ10606120 and A-438079. ATP-induced ethidium(+) uptake was also impaired by probenecid but not by 
carbenoxolone, both pannexin-1 antagonists. ATP induced YO-PRO-1(2+) and propidium(2+) uptake into 
KG-1 cells. Finally, sequencing of full-length P2X7 cDNA identified several single nucleotide 
polymorphisms (SNPs) in KG-1 cells including H155Y, A348T, T357S and Q460R. RPMI 8226 cells 
contained A348T, A433V and H521Q SNPs. In conclusion, the KG-1 cell line expresses functional P2X7. 
This cell line may help elucidate the signalling pathways involved in P2X7-induced survival and 
invasiveness of myeloid leukaemic cells. 
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Abstract 
The P2X7 purinergic receptor is an ATP-gated cation channel with an emerging role in neoplasia. 
In this study we demonstrate that the human KG-1 cell line, a model of acute myelogenous 
leukaemia, expresses functional P2X7. RT-PCR and immunochemical techniques demonstrated the 
presence of P2X7 mRNA and protein respectively in KG-l cells, as well as in positive control 
multiple myeloma RPMI 8226 cells. Flow cytometric measurements demonstrated that ATP 
induced ethidium+ uptake into KG-l cells suspended in sucrose medium (EC50 of ~3 µM), but not 
into cells in NaCl medium. In contrast, ATP induced ethidium+ uptake into RPMI 8226 cells 
suspended in either sucrose or NaCl medium (EC50 of ~3 or ~99 µM, respectively), as well as into 
RPMI 8226 cells in KCl medium (EC50 of ~18 µM). BzATP and to a lesser extent ATPγS and αβ-
methylene ATP, but not ADP or UTP, also induced ethidium+ uptake into KG-1 cells. ATP-induced 
ethidium+ uptake was completely impaired by the P2X7 antagonists, AZ10606120 and A-438079. 
ATP-induced ethidium+ uptake was also impaired by probenecid but not by carbenoxolone, both 
pannexin-1 antagonists. ATP also induced YO-PRO-12+ and propidium2+ uptake into KG-1 cells. 
Finally, sequencing of full-length P2X7 cDNA identified several single nucleotide polymorphisms 
(SNPs) in KG-1 cells including H155Y, A348T, T357S and Q460R. RPMI 8226 cells contained 
A348T, A433V and H521Q SNPs. In conclusion, the KG-1 cell line expresses functional P2X7. 
This cell line may help elucidate the signalling pathways involved in P2X7-induced survival and 
invasiveness of myeloid leukaemic cells. 
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The P2X7 purinergic receptor is a trimeric ATP-gated cation (Ca2+, Na+ and K+) channel present on 
various cell types [1]. Prolonged activation of P2X7 by extracellular ATP causes the uptake of 
organic cations, including ethidium+, and various downstream signalling events [1]. P2X7 plays 
important roles in inflammation and immunity, as well as in bone, epithelial and neuronal 
homeostasis [2, 3]. P2X7 also has an emerging role in neoplasia [4, 5]. Down-regulation of P2X7 
may act as a tumour escape mechanism by preventing ATP-induced cell death [6]. Alternatively, 
P2X7 activation may promote ATP-induced tumour cell survival and growth [7, 8]. P2X7 activation 
may also facilitate tumour invasiveness and metastases [9] by inducing the release of matrix 
membrane metalloproteases [10] and cysteine cathepsins [11], and the shedding of cell adhesion 
molecules [12, 13]. Despite these findings however, the role of P2X7 in neoplasia remains poorly 
defined. This, in large part, is due to the lack of human tumour cell lines suitable for the study of 
P2X7, with many cell lines failing to express this receptor [14] despite the detection of P2X7 in 
various malignant tissues [15, 16]. Therefore, using molecular, immunochemical and 
pharmacological approaches we investigated whether the human KG-1 cell line, a commonly used 
model of acute myelogenous leukaemia [17], expresses functional P2X7 receptors. 
 
Materials and methods 
 
Materials RPMI-1640 medium, GlutaMAX, YO-PRO-1 iodide and probenecid were from 
Invitrogen (Grand Island, NJ, USA). Foetal calf serum was from Lonza (Basel, Switzerland) or 
Bovogen Biologicals (East Kellior, Australia). Bovine serum albumin (BSA) and ethidium bromide 
were from Amresco (Solon, OH, USA). Nucleotides, propidium iodide and carbenoxolone were 
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from Sigma Chemical Co (St Louis, MO, USA). AZ10606120 and A-438079 were from Tocris 
Bioscience (Ellisville, MO, USA). 
 
Cell lines KG-1 and RPMI 8226 cells (European Collection of Cell Cultures, Porton Down, UK) 
were maintained in complete culture medium (RPMI-1640 medium containing 2 mM GlutaMAX, 
and 20% or 10% foetal calf serum, respectively) at 37oC/5% CO2. 
 
P2X7 expression Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer's instructions. RT-PCR of P2X7 mRNA was performed using 
Superscript III One-Step RT-PCR System Platinum Taq DNA polymerase (Invitrogen) as described 
[18]. Immunoblotting of whole cell lysates (the equivalent of 2 x 105 cells per lane) was performed 
using a rabbit anti-rat P2X7 polyclonal antibody (pAb) (Alomone Labs, Jerusalem, Israel) as 
described [18]. A rabbit anti-actin pAb (Sigma Chemical Co) was used to confirm equal protein 
loading as described [18]. Mean fluorescence intensity (MFI) of cell-surface P2X7 expression was 
detected using an Alexa Fluor 647-conjugated murine anti-human P2X7 monoclonal antibody 
(mAb) (clone L4) and flow cytometry as described [14]. 
 
Organic cation uptake measurements Nucleotide-induced organic cation uptake into cells 
suspended in either sucrose (280 mM sucrose, 5 mM KCl, 10 mM N-methyl-D-glucamine, 5 mM 
glucose, 0.1% BSA, 10 mM HEPES, pH 7.4), NaCl (145 mM NaCl, 5 mM KCl, 5 mM glucose, 
0.1% BSA, 10 mM HEPES, pH 7.4) or KCl (150 mM KCl, 5 mM glucose, 0.1% BSA, 10 mM 
HEPES, pH 7.4) medium was determined using a fixed-time flow cytometric assay as described 
[14]. The fluorescence of the organic cations ethidium+, YO-PRO-12+ and propidium2+ were 
collected with band pass filters 575/26, 515/20 and 695/40, respectively. 
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cDNA sequencing Total RNA was isolated as above. RT-PCR was performed using the MyTaq 
One-Step RT-PCR Kit (Bioline, Sydney, Australia) according to the manufacturer’s instructions 
using primer pairs (GeneWorks, Hindmarsh, Australia) specific for four overlapping regions of full 
length P2X7 cDNA including parts of the untranslated 5’ and 3’ ends. The primer pairs (forward 
and reverse, respectively) were: (1) 5’-tggccctgtcaggaagagta-3’ and 5’-caccaggcagagacttcaca-3’; (2) 
5’-ttgtaaaaagggatggatgga-3’ and 5’-aaatatgggagcgacagcag-3’; (3) 5’-tacatcggctcaaccctctc-3’ and 5’-
gaacagctctgaggtggtga-3’; and (4) 5’-gtctggtgccagtgtggaa-3’ and 5’-actcccgacctcaggtgat-3’. The 
PCR cycling conditions were 45°C for 20 min, 95°C for 1 min, 40 cycles of 95°C for 10 s, 63°C 
(primer pair 1), 59°C (primer pair 2), 62°C (primer pair 3) or 61°C (primer pair 4) for 10 s, and 
72°C for 30 s, and a final step of 72°C for 5 min. Amplicons were ran on 2% agarose gels, 
visualized by ethidium bromide staining, excised and purified using the Wizard SV Gel and PCR 
Clean-Up System (Promega, Madison, WI, USA) according to the manufacturer’s instructions. 
Purified amplicons were sequenced using the above primers with the BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, Carlsbad, CA, USA) and an Applied Biosystems 
3130xl Genetic Analyzer. PCR cycling conditions for sequencing were 95°C for 2 min, and then 25 
cycles of 96°C for 30 s, 55°C for 15 s and 60°C for 4 min. 
 
Data presentation and statistics Data are presented as mean ± SD. Differences between treatments 
were compared using either the unpaired Student's t-test for single comparisons to control samples 
or ANOVA for multiple comparisons (using Tukey's post test) using Prism 5 (Mac OS X Version 
5.0a; GraphPad Software, San Diego, CA, USA). Concentration response curves of log(agonist) vs. 







RT-PCR demonstrated P2X7 mRNA expression in KG-1 cells, as well as in positive control RPMI 
8226 cells (Fig. 1A), a human multiple myeloma cell line which expresses high amounts of 
functional P2X7 [14]. Immunoblotting with an anti-P2X7 pAb revealed the presence of a major 
band at 75 kDa, the predicted size of glycosylated P2X7, in both cell types (Fig. 1B). A minor band 
at 42 kDa was also observed in both cell lines (Fig. 1B). The amount of P2X7 was lower in KG-1 
cells compared to RPMI 8226 cells, despite equal protein loading as demonstrated using an anti-
actin pAb (Fig. 1B). Finally, immunolabelling with an anti-P2X7 mAb and flow cytometric analysis 
demonstrated cell-surface P2X7 expression on KG-1 cells, which was significantly lower than that 
on RPMI 8226 cells (MFI of 3.3 ± 0.4 and 17.0 ± 3.2 respectively, n=3, P<0.01; Fig. 1C). 
Preliminary experiments demonstrated that incubation of KG-1 cells suspended in NaCl 
medium with 1 mM ATP for up to 20 min failed to induce ethidium+ uptake into these cells, despite 
significant ethidium+ uptake into RPMI 8226 cells in NaCl medium after 5 min ATP incubation 
(results not shown). Therefore, ATP-induced ethidium+ uptake into KG-1 cells was next assessed in 
sucrose medium, which can facilitate P2X7-induced cation uptake in other cell types [19, 20]. A 20 
min incubation with ATP induced significant ethidium+ uptake into KG-1 cells in a concentration–
dependent manner, with a maximal uptake at 100 µM ATP and with an EC50 of 3.3 ± 1.3 µM (Fig. 
2A). This EC50 value is typical of cation fluxes mediated by recombinant human P2X7 expressed in 
cell lines in sucrose medium [19]. Moreover, this EC50 value was similar to the EC50 value (2.7 ± 
2.7 µM) for ATP-induced ethidium+ uptake into RPMI 8226 cells suspended in sucrose medium 
(Fig. 2B). In contrast, the EC50 values for ATP-induced ethidium+ uptake into RPMI 8226 cells 
suspended in either KCl or NaCl medium were higher (17.8 ± 8.2 or 99.3 ± 19.6 µM respectively) 
(Fig. 2B). The latter EC50 value was similar to that previously observed for RPMI 8226 cells in 
NaCl medium [14]. 
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To determine whether the ATP-induced ethidium+ uptake into KG-1 cells was mediated by 
P2X7, cells suspended in sucrose medium were incubated in the absence or presence of ATP, the 
most potent P2X7 agonist BzATP, the partial P2X7 agonist ATPγS, or agonists of other P2 
receptors. As above, 100 µM ATP induced a significant amount of ethidium+ uptake (Fig. 3A). 
Similarly, 100 µM BzATP, and to a lesser extent 100 µM ATPγS also induced significant ethidium+ 
uptake (Fig. 3A). Surprisingly, 100 µM αβ-methylene ATP, which is not a recognized P2X7 
agonist, also induced a small but significant uptake of ethidium+ (Fig. 3A). In contrast, neither 100 
µM ADP or UTP caused a significant amount of ethidium+ uptake into KG-1 cells (Fig. 3A). To 
confirm that this ATP-induced ethidium+ uptake was mediated by P2X7, KG-1 cells were pre-
incubated in the absence or presence of the P2X7 antagonists, AZ10606120 or A-438079, and the 
relative amounts of ATP-induced ethidium+ uptake into KG-1 cells suspended in sucrose medium 
measured. Pre-incubation of cells with 100 nM AZ10606120 or 10 µM A-438079 completely 
inhibited 100 µM ATP-induced ethidium+ uptake (Fig. 3B). Neither antagonist significantly altered 
ethidium+ uptake in the absence of ATP (Fig. 3B). 
Debate exists over the cut-off size of the P2X7 pore. Therefore, in addition to ethidium+ (314 
Da) above, the effect of ATP incubation on YO-PRO-12+ (375 Da) and propidium2+ (415 Da) 
uptake into KG-1 cells suspended in sucrose medium was assessed. ATP induced significant uptake 
of both YO-PRO-12+ and propidium2+ (Fig. 3C). Debate also exists over the molecular identity of 
the P2X7 pore; in particular the hemichannel pannexin-1 may function as the P2X7 pore [21]. 
Therefore, KG-1 cells were pre-incubated in the absence or presence of the pannexin-1 antagonists, 
probenecid or carbenoxolone, and the relative amounts of ATP-induced ethidium+ uptake into KG-1 
cells suspended in sucrose medium measured. Cells were pre-incubated with probenecid or 
carbenoxolone at concentrations reported to block pannexin-1 [21, 22]. Pre-incubation of cells with 
2 mM probenecid significantly inhibited 100 µM ATP-induced ethidium+ uptake (Fig. 3D). In 
contrast, 20 µM carbenoxolone failed to alter 100 µM ATP-induced ethidium+ uptake (Fig. 3D). 
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Neither antagonist significantly altered ethidium+ uptake in the absence of ATP (Fig. 3D). 
The above data indicates that the low amount of P2X7 function in KG-1 cells, compared to 
RPMI 8226 cells, corresponds to low P2X7 expression. To determine if this low P2X7 function in 
KG-1 cells may be attributed to single nucleotide polymorphisms (SNPs) that alter P2X7 expression 
or function, full length P2X7 cDNA from these cells was amplified by RT-PCR and sequenced. 
Full length P2X7 cDNA from RPMI 8226 cells was also amplified and sequenced as a comparison. 
The p2x7 gene of KG-1 cells was heterozygous for six non-synonymous and three synonymous 
SNPs (Table 1). Of note, these cells contained the loss-of-function SNP, T357S [23], two gain-of-
function SNPs, H155Y [24] and A348T [25, 26], and the Q460R SNP, which uniquely identifies 
the gain-of-function haplotype variant P2X7-4 [26]. The p2x7 gene of RPMI 8226 cells was 
homozygous for three non-synonymous and two synonymous SNPs (Table 1). Of note, these cells 
contained the A348T gain-of-function SNP, as well as the H521Q SNP, which reduces the 
sensitivity of the receptor to inhibition by extracellular Ca2+ [25]. Neither cell line encoded other 
P2X7 SNPs (reviewed in [1, 3] including well-characterised SNPs such as R307Q, E496A and 




In the current study, we demonstrate that the acute myelogenous leukaemic KG-1 cell line 
expresses functional P2X7 receptors. First, RT-PCR, and immunoblotting and immunolabelling 
demonstrate the presence of P2X7 mRNA and protein in KG-1 cells, respectively. Second, ATP 
induced ethidium+ uptake into KG-1 cells with an EC50 of ~3 µM, a value typical of cation fluxes 
mediated by recombinant human P2X7 expressed in cells in sucrose medium [19] or endogenous 
P2X7 in RPMI 8226 cells in sucrose medium (this study). Third, the most potent P2X7 agonist 
BzATP, as well as the partial P2X7 agonist ATPγS, induced ethidium+ into KG-1 cells. Fourth, the 
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P2X7 antagonists, AZ10606120 and A-438079, prevented ATP-induced ethidium+ uptake into KG-
1 cells. 
The amount of functional P2X7 on KG-1 cells is relatively low compared to other cell lines. 
Previously, we have shown that 5 min ATP incubation of either RPMI 8226 cells, murine 
erythroleukaemia cells or murine RAW264.7 macrophages in NaCl medium results in significant 
ethidium+ uptake [14, 27]. In comparison, up to 20 min incubation with ATP failed to induce 
significant ethidium+ uptake into KG-1 cells in NaCl medium. This relatively low amount of 
functional P2X7 in KG-1 cells is most likely attributed to the low amounts of cell-surface P2X7, as 
observed when compared to RPMI 8226 cells. This low amount of cell-surface P2X7 corresponded 
with reduced P2X7 mRNA and total protein expression in KG-1 cells compared to RPMI 8226 
cells. The RT-PCR assay used however was not quantitative nor did it include a house-keeping 
gene. 
In addition to the low amount of P2X7 expression in KG-1 cells, these cells where 
heterozygous for the loss-of-function T357S SNP, which may further explain the reduced P2X7 
function in KG-1 cells. The KG-1 cells were also heterozygous for the partial loss-of-function 
Q460R SNP, although the negative effect of this SNP on P2X7 function [26] has not been observed 
by others [25]. Moreover, in Caucasians (from which KG-1 cells originate), the Q460R SNP 
uniquely identifies a haplotype variant termed P2X7-4, which contains the gain-of-function SNPs, 
H115Y and A348T (but is wild-type at residue 357), and results in a net gain of function [26]. 
Nevertheless, given that the T357S SNP in heterozygous dosage reduces P2X7 function by at least 
50% in primary leukocytes from all subjects studied [23], it remains likely that the allele coding for 
S357 (and uniquely associated with haplotype variant P2X7-5) may have a dominant negative effect 
on other P2X7 alleles (including that containing P2X7-4) resulting in a net loss of function. KG-1 
cells also contained two other non-synonymous SNPs, L320P and P582L, however their effect on 
P2X7 expression or function remains unknown. A study of rat P2X7, demonstrated that a P582G 
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mutation fails to alter P2X7 channel or pore formation, although using truncated P2X7 variants this 
same study identified P582 as part of a pore-enabling region (551-582) which regulates cell-surface 
P2X7 expression and thereby P2X7 function [28]. As a result, these authors hypothesised that 
mutations within this region may prevent cell-surface P2X7 expression [28]. Thus the possibility 
remains that P582L may reduce P2X7 function as a result of reduced cell-surface P2X7 expression. 
Alternatively, the L320P SNP, which resides within the ATP-binding site of P2X receptors [29], 
may result in an atypical pharmacology and contribute to the low P2X7 function in KG-1 cells. 
Atypical P2X7 pharmacology has also been observed in human osteosarcoma MG63 and SaOS2 
cells [30]. Moreover, αβ-methylene ATP, which is not a recognised P2X7 agonist, induced a small 
but significant uptake of ethidium+ into KG-1 cells. Nucleotide preparations however can contain 
small amounts of contaminating ATP [31]. Thus, comparison of the ATP concentration response 
and agonist data suggests that as little as a 1% contaminating ATP may have contributed to the αβ-
methylene-induced ethidium+ uptake into KG-1 cells. Finally, we cannot exclude that KG-1 cells 
contain an alternate P2X7 isoform, rather than a SNP, that reduces P2X7 function as observed in 
various human epithelial cervical cancer cell lines [6]. 
The presence of p2x7 SNPs in cell lines is not unique to KG-1 cells. The human acute 
monocytic leukaemic THP-1 cell line is heterozygous for the loss-of-function E496A SNP [14, 32], 
while others have shown that human myelomonocytic leukaemic J6-1 cells contain the loss-of-
function N187D SNP [33]. Moreover, the current study reveals that RPMI 8226 cells are 
homozygous for the gain-of-function A348T SNP, as well as A433V and H521Q. The presence of 
threonine at position 348 may account for the higher P2X7 function of RPMI 8226 cells compared 
to KG-1 cells. Although not formally demonstrated, A433V may also act as an additional gain-of-
function SNP in these cells as the opposite amino acid exchange at position 76 of P2X7 (V76A) 
causes a loss of function [26]. Finally, others have shown that H521Q has no effect on ATP-
induced ethidium+ uptake, but can reduce the sensitivity of P2X7 to inhibition by extracellular Ca2+ 
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[25]. In this regard, maximal ATP-induced ethidium+ uptake into RPMI 8226 cells is similar in cells 
suspended in either NaCl medium containing Ca2+/Mg2+ or nominally free of Ca2+/Mg2+ [14]. 
The current study also demonstrates that P2X7 activation induces uptake of organic cations 
up to and including the size of propidium2+ (415 Da) into KG-1 cells. P2X7 activation induces 
ethidium+ (314 Da) but not propidium2+ uptake into human lymphocytes [34], dendritic cells [35] 
and THP-1 cells [18]. In contrast, P2X7 activation induces uptake of propidium2+ into rat bone 
nodule cells [36] and P2X7-transfected HEK-293 cells [37]. Reasons for differences between these 
cells, especially between the myeloid cell types (KG-1, dendritic and THP-1 cells) remain 
unknown. These differences may be due to technical reasons; both of the myeloid cell studies that 
failed to show P2X7-induced propidium2+ uptake were conducted with cells suspended in KCl 
medium, while P2X7-induced propidium2+ uptake into KG-1 cells was conducted with cells 
suspended in sucrose medium. Alternatively, the observed differences in P2X7-induced 
propidium2+ uptake between different cell types may reflect differences in the molecular identity of 
the P2X7 pore or in the propensity of P2X7 to dilatate. Attempts to characterize the molecular 
identity of the P2X7 pore in KG-1 cells using pannexin-1 antagonists suggest that the P2X7 pore in 
KG-1 cells is not pannexin-1 or that pannexin-1 is dispensable for P2X7-induced pore formation. 
ATP-induced ethidium+ uptake was completely blocked by probenecid but unaffected by 
carbenoxolone. Although probenecid can block pannexin-1 [22], it has long been recognised that 
probenecid blocks other molecules within cells [38]. Thus, the possibility remains that the P2X7 
pore may be a molecule other than pannexin-1. Alternatively, probenecid may directly block P2X7 
to prevent pore formation. Regardless, the lack of evidence for pannexin-1 as the P2X7 pore in KG-
1 cells is consistent with studies using cells from pannexin-1 knockout mice, which are permeable 
to organic cations following ATP incubation [39]. 
P2X7 has been reported in various primary lymphoid and myeloid leukaemias in humans 
[40-44], however the pathophysiological significance of P2X7 in these malignant cell types remains 
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unknown. Evidence indicates that the relative P2X7 expression and/or function directly correlates 
with the progression of chronic lymphocytic leukaemia [40] or acute myelogenous leukaemia [44] 
suggesting a role for increased P2X7 activity in promoting these leukaemias. Studies confirming 
these observations however are lacking. Nevertheless the detection of functional P2X7 in KG-1 
cells indicates that this cell line may provide a model to study the role of P2X7 in acute 
myelogenous leukaemia. For example, this cell line may be useful in determining if ATP induces 
death or survival in acute myelogenous leukaemic cells, and identifying the signalling pathways 
involved in either of these processes. Alternatively, given that KG-1 cell migration can be studied in 
vitro [45], and the potential role of P2X7 in facilitating tumour invasiveness and metastases [5], the 
KG-1 cell line might provide a useful model to further elucidate the role of P2X7 and downstream 
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Fig. 1 KG-1 cells express P2X7. (A) RNA isolated from KG-1 and RPMI 8226 cells was amplified 
by RT-PCR using primers to P2X7 and products examined by agarose gel electrophoresis. (B) 
Whole cell lysates from KG-1 and RPMI 8226 cells were separated by SDS-PAGE, transferred to 
nitrocellulose membrane and probed with anti-P2X7 (top panel) or anti-actin (bottom panel) pAb. 
(C) KG-1 and RPMI 8226 cells were labeled with Alexa Fluor 647-conjugated P2X7 (solid line) or 
isotype control (shaded) mAb, and the relative cell-surface P2X7 expression measured by flow 
cytometry. Representative results from (A,B) two or (C) three experiments shown. 
 
Fig. 2 ATP induces ethidium+ uptake into KG-1 cells. (A) KG-1 cells in sucrose medium or (B) 
RPMI 8226 cells in sucrose, KCl or NaCl medium were incubated with 25 µM ethidium+ in the 
presence of varying amounts of ATP (as indicated) at 37oC for (A) 20 or (B) 5 min. Incubations 
were stopped by MgCl2 solution and centrifugation, and ethidium+ uptake measured by flow 
cytometry. Ethidium+ uptake is expressed as percent maximum response compared to 1 mM ATP 
for each corresponding medium; results are mean ± SD (A, n=3; B, n=9). 
 
Fig. 3 P2X7 activation mediates organic cation uptake into KG-1 cells. (A-D) KG-1 cells were 
suspended in sucrose medium. (A) Cells were incubated with 25 µM ethidium+ in the absence 
(Basal) or presence of 100 µM nucleotide (as indicated; αβMethATP, αβ-methylene ATP) at 37oC 
for 20 min. Cells were pre-incubated (B) with DMSO or 100 nM AZ10606120 (left panel), in the 
absence (Control) or presence of 10 µM A-438079 (right panel), (D) in the absence (Control) or 
presence of 2 mM probenecid (left panel), or in the absence (Control) or presence of 20 µM 
carbenoxolone (right panel) at 37oC for 15 min. Cells were then incubated with (B,D) 25 µM 
ethidium+, (C) 1 µM YO-PRO-12+ or 25 µM propidium2+ (B-D) in the absence (Basal) or presence 
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of 100 µM ATP at 37oC for 20 min. (A-D) Incubations were stopped by MgCl2 solution and 
centrifugation, and cation uptake measured by flow cytometry. Results are mean ± SD (n=3-6); 
*P<0.05 or **P<0.01 compared to corresponding basal, ††P<0.01 compared to corresponding ATP 
alone. 
Table 1 KG-1 and RPMI 826 cells contain several single nucleotide polymorphisms in the p2x7 gene 
dbSNP rs# 
Cluster IDa 




KG-1 RPMI 8226 
rs28360448 GTG>GTA V154V Synonymousc Wild-type Homozygous 
rs208294 CAT>TAT H155Y Gain Heterozygous Wild-type 
rs73403850 CTG>CCG L320P Unknown Heterozygous Wild-type 
rs1718119 GCT>ACT A348T Gain Heterozygous Homozygous 
rs2230911 ACT>AGT T357S Loss Heterozygous Wild-type 
rs28360459 GCG>GTG A433V Unknown Wild-type Homozygous 
rs2230912 CAG>CGG Q460R Possible loss Heterozygous Wild-type 
rs3751144 CCC>CCT P474P Synonymous Heterozygous Wild-type 
rs2230913 CAC>CAG H521Q Neutrald Wild-type Homozygous 
rs3751142 CTG>CTT L534L Synonymous Heterozygous Wild-type 
rs77111027 CCG>CTC P582L Unknown Heterozygous Wild-type 
rs1621388 CCG>CCA P582P Synonymous Heterozygous Homozygous 
ahttp://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=5027. 
bFull length P2X7 cDNA from KG-1 and RPMI 8226 cells was amplified by RT-PCR and 
sequenced to identify potential base changes (single nucleotide polymorphisms). 
cEach synonymous mutation is predicted to have neutral effect on function. 
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